Denosumab for hypercalcaemia of malignancy (1198)
Warning
Denosumab is a human monoclonal antibody that can be used for the treatment of hypercalcaemia of malignancy. This guideline advises on prescribing and dosing of denosumab instead of standard treatment with zolendronic acid where the condition is refractory to bisphosphonate therapy or where bisphosphonates are contraindicated due to severe renal impairment, under the guidance of the Specialist Palliative Care Team. This guideline should be considered in conjunction with the Scottish Palliative Care Guideline on Management of hypercalcaemia.